Diligence memo · auto-generated · as of July 3, 2026
Notch Therapeutics, Inc.
Notch Therapeutics, Inc. looks under-valued against its niche peers and is quiet on financing cadence.
Businessfiled
Notch Therapeutics, Inc. operates in Pharma, based in VANCOUVER.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Notch Therapeutics, Inc. has raised $15M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $15M on 2024-05-17.
Most recent recorded round closed around 2024-05-17.
Valuation (modeled)modeled
Provath models Notch Therapeutics, Inc. at approximately $114M (range $33M–$209M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.54× the median modeled value of Series B Pharma companies in 2022–2024 (7 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 2.1 yr ago; this sector typically re-raises about every 16 months.
Slightly overdue versus sector cadence.
Comparablesmixed
Capital scale ranks ahead of 74% of Pharma peers (310 compared).
Modeled value ranks above 68% of those peers.
Closest niche peers: Switch Therapeutics Inc., March Therapeutics, Inc., Affect Therapeutics, Inc., SPR Therapeutics, Inc., Multiply Labs, Inc..
Peoplefiled
10 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.